QTTB
Q32 Bio Inc.
A maker of biologic medicines that calm an overactive immune system, Q32 Bio develops antibody treatments for autoimmune and inflammatory diseases. Its lead drug candidate, bempikibart, is being studied for alopecia areata, an autoimmune condition that causes hair loss. The Waltham, Massachusetts company began in 2017 as AdMIRx and renamed itself Q32 Bio in 2020 — a name it has never publicly explained.
CUSIP: 746964105HealthcareUS1 holder
Recent Activity
2025Q1
1 sell
-81.5K shares
-81.5K shares
Loading more activity...